← The record

High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein Carbohydrate

Recommended · restricted MetabolicRestrictedNot applicable line

Ketogenic diet for patients with intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency.

1
Submissions
2016–16
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Nov 2016
    Recommended · restricted

    vs KetoCal 4:1 LQ®

  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC recommended the listing of Keyo® as a Restricted Benefit for patients requiring a Ketogenic diet.PSD · Nov 2016
6.2 The PBAC noted the advice of the Nutritional Products Working Party (NPWP) that supported the listing of Keyo® on the PBS.PSD · Nov 2016

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated as this is a minor submission with no economic comparison required.

The PBAC agreed with the advice of the NPWP that the price should be on a cost minimisation basis with the comparator KetoCal 4:1LQ. PBAC · 2016
Cost-effectiveness accepted

Decision context

PopulationPatients aged 1–10 years requiring a ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2016 Recommended · restricted KetoCal 4:1 LQ® Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to specific neurometabolic conditions (intractable seizures, glucose transport defect, pyruvate dehydrogenase deficiency) and age 1–10 years; TGA label covers all food for special medical purposes.